AZD-3463是可口服的ALK选择性抑制剂，K_i为0.75 nM，具有抗肿瘤活性。ALK主要表达于于神经元，其高表达与神经母细胞瘤的不良预后有关。

参考文献

[1] Wang Y, Wang L, Guan S, et al. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep. 2016 Jan 20;6:19423. doi: 10.1038/srep19423(IF:4.011).

[2] Moharram SA, Shah K, Khanum F, et al. The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood Cancer J. 2019 Jan 15;9(2):5. doi: 10.1038/s41408-018-0169-1(IF:7.895).

-25~-15℃保存，有效期3年。